Skip to Content

Posts tagged with "Press Coverage"

  • Cancer

    Jungle Rot

    There are all sorts of excellent reasons not to cut down the rainforests of Borneo. Biological diversity, erosion, local climate, sheer aesthetics. . .no one should have to scratch their head for very long. But this isn’t one of them, at least not the way it’s being sold: “Plants thought to help treat or cure… Read More
  • Press Coverage

    Full Disclosure

    Some readers will have heard that Michael Fumento, well-known pundit and controversialist, has been fired from his post at Scripps-Howard. Eamon Javers of Business Week broke the story of how Fumento had received some $60,000 from Monsanto without disclosing the relationship. If you look in the comments after that article, you’ll see a lot of… Read More
  • Press Coverage

    Well-Rounded?

    Nicholas Kristof had a column today (available on one of those private, subscription-only web sites here) with the title “The Hubris of the Humanities”. It’s a C.P. Snow-style “Two Cultures” lament, but at least it’s one from the non-science side of the gap: “In the U.S. and most of the Western world, it… Read More
  • Press Coverage

    Okadaic Acid Makes Vanity Fair

    Reader Jeff G. pointed out this blog post, which quotes the letters column in the most recent issue of Vanity Fair. The magazine ran a profile of Paris Hilton, about whom the less said the better, and quoted her in-the-same-category sister, Nicky, to the effect that she was working so hard, running multimillion-dollar companies and… Read More
  • Press Coverage

    Gene to Drug: You Bet

    I mentioned that the Wall Street Journal is running a free-access week. That’ll give you a chance to check out the Nov. 11th column by their science columnist, Sharon Begley, who sounds an appropriate note of caution about genomic-based drug discovery. (And I’m not saying that just because she quotes me). It’ll be good to… Read More
  • Press Coverage

    Say It Again!

    From the editorial pages of the Washington Post we have this, and I could not have said it better myself: . . .Unfortunately for Merck, scientific facts didn’t play much of a role in the first Vioxx trial, which ended on Aug. 19. The Texas jury in that case awarded $253.4 million to the widow… Read More
  • Press Coverage

    “. . .And to Furbish Falsehoods For a Magazine”

    I couldn’t resist linking to this article, part of a series in the Guardian. I’m afraid that he’s pretty much on target for most science stories in the news: “Science is done by scientists, who write it up. Then a press release is written by a non-scientist, who runs it by their non-scientist boss, who… Read More
  • Current Events

    Okay, One More Merck Point

    You know, there is one more thing about the Merck case I’d like address. This is brought on partly by the general press coverage of whether Merck knew this or hid that, and partly by an intensely irritating comment to Friday afternoon’s post. You would think, to hear the way some people talk, that no… Read More
  • Press Coverage

    The Place to Be

    Glenn Reynolds, of Instapundit fame, has some nice things to say about the drug industry in this piece on MSNBC.com. I appreciate it; we need all the good press we can get these days. Says Glenn: “The pharmaceutical industry isn’t beyond criticism, of course. But I find most of the criticism rather strained, and all… Read More
  • Press Coverage

    At Your Newsstand Today

    I’d like to recommend the latest issue of Science, which has a multi-part special section on drug discovery. (Problem is, that link will only work if you’re a subscriber, and none of the content is outside the wall.) I’m not just plugging the articles because one of them quotes me, although that was a nice… Read More
...91011...